Alzheimer's disease Other Imaging Findings: Difference between revisions
No edit summary |
Akshun Kalia (talk | contribs) No edit summary |
||
Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
Other imaging studies in Alzheimer's include positron emission tomography (PET) and single photon emission computed tomography (SPECT) scan. PET and SPECT scan are not routinely done in Alzheimer's disease. However, patients with atypical presentation may be evaluated with either a PET or SPECT scan to further assess the patient for any underlying condition. In these patients, use of amyloid β PET scan will reveal lower FDG (fluorine-18 fluorodeoxyglucose) metabolism and higher PiB ([11 C]Pittsburgh compound B) deposition in areas of the brain affected by Alzheimer's disease. | |||
==Other Imaging Findings== | |||
Other imaging studies in Alzheimer's include positron emission tomography (PET) and single photon emission computed tomography (SPECT) scan. PET and SPECT scan are not routinely done in Alzheimer's disease. However, patients with atypical presentation may be evaluated with either a PET or SPECT scan to further assess the patient for any underlying condition. | |||
The Amyloid Imaging Taskforce (AIT) recommends use of amyloid β (Aβ) positron emission tomography (PET) scanning in atypical cases of Alzheimer's. The tracer used in PET scan for amyloid β include [11 C]Pittsburgh compound B (PiB) and fluorine-18 fluorodeoxyglucose(FDG). Patients with greater decline in memory function have lower FDG metabolism and higher PiB deposition in areas of the brain affected by Alzheimer's disease. According to the guidelines of AIT, amyloid β PET scan is recommended in cases of: | |||
*Patients with persistent or progressive unexplained mild cognitive impairment | |||
*Patients with early age onset | |||
*Patients with progressive dementia. | |||
*There are no specific imaging findings associated with Alz. | |||
*There are no | |||
*[Imaging modality] may be helpful in the diagnosis of [disease name]. Findings on an [imaging modality] suggestive of/diagnostic of [disease name] include: | *[Imaging modality] may be helpful in the diagnosis of [disease name]. Findings on an [imaging modality] suggestive of/diagnostic of [disease name] include: |
Revision as of 13:51, 21 September 2017
Alzheimer's disease Microchapters |
Diagnosis |
---|
Treatment |
Alzheimer's disease Other Imaging Findings On the Web |
American Roentgen Ray Society Images of Alzheimer's disease Other Imaging Findings |
Risk calculators and risk factors for Alzheimer's disease Other Imaging Findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Other imaging studies in Alzheimer's include positron emission tomography (PET) and single photon emission computed tomography (SPECT) scan. PET and SPECT scan are not routinely done in Alzheimer's disease. However, patients with atypical presentation may be evaluated with either a PET or SPECT scan to further assess the patient for any underlying condition. In these patients, use of amyloid β PET scan will reveal lower FDG (fluorine-18 fluorodeoxyglucose) metabolism and higher PiB ([11 C]Pittsburgh compound B) deposition in areas of the brain affected by Alzheimer's disease.
Other Imaging Findings
Other imaging studies in Alzheimer's include positron emission tomography (PET) and single photon emission computed tomography (SPECT) scan. PET and SPECT scan are not routinely done in Alzheimer's disease. However, patients with atypical presentation may be evaluated with either a PET or SPECT scan to further assess the patient for any underlying condition. The Amyloid Imaging Taskforce (AIT) recommends use of amyloid β (Aβ) positron emission tomography (PET) scanning in atypical cases of Alzheimer's. The tracer used in PET scan for amyloid β include [11 C]Pittsburgh compound B (PiB) and fluorine-18 fluorodeoxyglucose(FDG). Patients with greater decline in memory function have lower FDG metabolism and higher PiB deposition in areas of the brain affected by Alzheimer's disease. According to the guidelines of AIT, amyloid β PET scan is recommended in cases of:
- Patients with persistent or progressive unexplained mild cognitive impairment
- Patients with early age onset
- Patients with progressive dementia.
- There are no specific imaging findings associated with Alz.
- [Imaging modality] may be helpful in the diagnosis of [disease name]. Findings on an [imaging modality] suggestive of/diagnostic of [disease name] include:
- [Finding 1]
- [Finding 2]
- [Finding 3]